{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:42:11Z","timestamp":1788176531278,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41409-025-02789-7","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:47:31Z","timestamp":1768582051000},"page":"480-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Results of brexucabtagene-autoleucel for patients with relapsed\/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland"],"prefix":"10.1038","volume":"61","author":[{"given":"Linda","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Luisa","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-2725","authenticated-orcid":false,"given":"Enver","family":"Aydilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0728-2253","authenticated-orcid":false,"given":"Eva-Maria","family":"Wagner-Drouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4876-802X","authenticated-orcid":false,"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"von Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-5491","authenticated-orcid":false,"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Koenecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6830-9296","authenticated-orcid":false,"given":"Stephan","family":"Stilgenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-5839","authenticated-orcid":false,"given":"Fabian","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith S.","family":"Hecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Brunnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaus","family":"Kroeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Kronfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Theobald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Ohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8743-6752","authenticated-orcid":false,"given":"Irene","family":"Schmidtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9282-5688","authenticated-orcid":false,"given":"Georg","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8570","authenticated-orcid":false,"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2789_CR1","doi-asserted-by":"publisher","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Campo E, Hermine O, Jerkeman M, Le Gouill S, Rule S, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv62\u2013iv71. https:\/\/doi.org\/10.1093\/annonc\/mdx223.","journal-title":"Ann Oncol"},{"key":"2789_CR2","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"key":"2789_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70062","volume":"9","author":"S Stock","year":"2025","unstructured":"Stock S, B\u00fccklein VL, Blumenberg V, Magno G, Emhardt A, Holzem AME, et al. Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. HemaSphere. 2025;9:e70062. https:\/\/doi.org\/10.1002\/hem3.70062.","journal-title":"HemaSphere"},{"key":"2789_CR4","doi-asserted-by":"publisher","unstructured":"Herbaux C, Bret C, Bachy E, Bories P, Di Blasi R, Cuffel A, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica 2024. https:\/\/doi.org\/10.3324\/haematol.2023.284786.","DOI":"10.3324\/haematol.2023.284786"},{"key":"2789_CR5","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. JCO. 2023;41:2594\u2013606. https:\/\/doi.org\/10.1200\/JCO.22.01797.","journal-title":"JCO"},{"key":"2789_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.87","volume":"8","author":"MA O\u2019Reilly","year":"2024","unstructured":"O\u2019Reilly MA, Wilson W, Burns D, Kuhnl A, Seymour F, Uttenthal B, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. HemaSphere. 2024;8:e87. https:\/\/doi.org\/10.1002\/hem3.87.","journal-title":"HemaSphere"},{"key":"2789_CR7","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","volume":"6","author":"G Iacoboni","year":"2022","unstructured":"Iacoboni G, Rejeski K, Villacampa G, Van Doesum JA, Chiappella A, Bonifazi F, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6:3606\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2021006922.","journal-title":"Blood Adv"},{"key":"2789_CR8","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1007\/s00277-023-05597-5","volume":"103","author":"P Yang","year":"2024","unstructured":"Yang P, Liu S-Z, Li C-Y, Zhang W-L, Wang J, Chen Y-T, et al. Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China. Ann Hematol. 2024;103:2381\u201391. https:\/\/doi.org\/10.1007\/s00277-023-05597-5.","journal-title":"Ann Hematol"},{"key":"2789_CR9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015014","author":"N Ahmed","year":"2025","unstructured":"Ahmed N, Thiruvengadam S, Hamadani M, Hu Z-H, Grover NS, Shadman, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2024015014.","journal-title":"Blood Adv"},{"key":"2789_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.23.02470","volume":"43","author":"TJ Phillips","year":"2025","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trn\u011bn\u00fd, et al. Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study. JCO. 2025;43:318\u201328. https:\/\/doi.org\/10.1200\/JCO.23.02470.","journal-title":"JCO"},{"key":"2789_CR11","doi-asserted-by":"publisher","unstructured":"Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023. https:\/\/doi.org\/10.1002\/ajh.27056.","DOI":"10.1002\/ajh.27056"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02789-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:20:45Z","timestamp":1775571645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02789-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2789"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02789-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"27 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LS received honoraria or travel support from AstraZeneca, Incyte. VV received honoraria from Gilead\/Kit\u0119, Novartis, BMS Celgene, Janssen, KR received research funding from Kite\/Gilead, is an consultant and received honoraria and travel support from Novartis, BMS\/Celgene, Pierre-Fabre, CSL Behring. MLS reports honoraria and travel funds from Kite\/Gilead, Takeda, Janssen, and Sobi. EA received honoraria from AstraZeneca, Gilead, Janssen, Lilly. MT is an advisor or consultant for Janssen-Cilag, has received honoraria from BMS\/Celgene, Janssen-Cilag, BPM Pharma, Medothic GmbH. MF has received remuneration and financial support in form of travel support (Abbvie, Janssen J&J Innovative Medicine, Takeda, Kite\/Gilead), consulting and advisory fees (E.Lilly, Incyte, Kite\/Gilead). CL received honoraria for attending symposia and travel support from Pierre Fabre, BristolMyersSquibb, Janssen. CK received honoraria from Janssen, BMS, Novartis, Kite\/Gilead. JH received honoraria for consulting and travel support from J&J, Servier, Kite\/Gilead, Novartis, BMS\/Celgene, Iovance, Imatics. GH has received research support or contracts from Celgene, Kite, a Gilead Company, Incyte, Janssen, Morphosys, Pfizer, and Roche; has received honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbvie, ADC, AstraZeneca, Genmab, Kite\/Gilead, Incyte, Janssen, Morphosys, Novartis, Roche, and Takeda; has received support for attending meetings and\/or travel from Kite\/Gilead and Janssen; and has participated in on a Data Safety Monitoring Board or Advisory Board for Miltenyie. PD received consultancy from AbbVie, AstraZeneca, Bluebird Bio, Gilead, Janssen, Novartis, Riemser, and Roche; received speaker\u2019s bureau fees from AbbVie, AstraZeneca, Gilead, Novartis, Riemser, and Roche; and received research support from Riemser. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study is part of the EMCL-R and DRST which was approved by the Ethical Committee of Rhineland-Palatinate (Ref. Nr. 2018-13856). Written informed consent in accordance with the European data protection regulations and the Declaration of Helsinki was obtained from all participants alive. The registries allowed for inclusion of deceased patients without prior written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}